CCL25 and myeloid sarcoma: Among the identified molecules present both in CSF and serum samples of examined MS patients, four (IFNα2, APRIL, Pentraxin-3, and CCL25) were previously described as part of a CSF inflammatory pattern predictive of disease progression and severe cortical damage in MS patients after four years of clinical and imaging follow-up from the diagnosis [10].